Clindamycin Phosphate Topical Solution
In 18 clinical studies of various formulations of topical Clindamycin Phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].
Number of Patients Reporting Events
|Burning||62 (11)||15 (10)||17 (11)|
|Itching||36 ( 7 )||15 (10)||17 (11)|
|Burning/Itching||60 (11)||# (-- )||# (-- )|
|Dryness||105 (19)||34 (23)||29 (18)|
|Erythema||86 (16)||10 ( 7 )||22 (14)|
|Oiliness/Oily Skin||8 ( 1 )||26 (18)||12*(10)|
|Peeling||61 (11)||# (-- )||11 ( 7 )|
| # not recorded
* of 126 subjects
Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.
Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).
Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.
Read the Clindamycin Phosphate Topical Solution (clindamycin phosphate topical solution) Side Effects Center for a complete guide to possible side effects
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.
Last reviewed on RxList: 1/7/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Clindamycin Phosphate Topical Solution Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.